Robin Snead, MD
Internal Medicine · Chicago, ILNPI 1972695526
Payments from drug & device makers
Across 107 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$301
- Lilly USA, LLC$232
- Pfizer$231
- AstraZeneca$170
- Vanda Pharmaceuticals Inc.$152
- Johnson & Johnson$72
- plus $472 from 13 others
What the payments were for
- Food & beverage$1,61799%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $301 |
| Lilly USA, LLC | 16 | $232 |
| Pfizer | 17 | $231 |
| AstraZeneca | 11 | $170 |
| Vanda Pharmaceuticals Inc. | 6 | $152 |
| Johnson & Johnson | 4 | $72 |
| Amgen | 5 | $70 |
| Amarin Pharma, Inc. | 3 | $66 |
| Merck | 4 | $57 |
| GSK | 2 | $50 |
| Zyla Life Sciences, Inc. | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $37 |
| Corcept Therapeutics | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Optinose US, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $11 |
How this compares
$1,631 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $322 |
| Pregabalin | 14 | $286 |
| Atorvastatin Calcium | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.